Penn Medicine Provider
Medical Oncology
Kim A. Reiss, MD
5.0
(298)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West

About me

  • Assistant Program Director of the Hematology/Oncology Fellowship Program
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Pennsylvania State University College of Medicine
  • Residency: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital

What my patients think about me

Average Rating
5.0

298 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
she is great
May 2025
5.0
5.0
i have already recommended her
May 2025
5.0
5.0
knowledgeable, caring
May 2025
5.0
5.0
she was thorough and honest.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Reiss is a Penn Medicine physician.

Qualifications and experience

My research

Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations , Oral Abstract Session, ASCO 2025, Chicago, IL: 2025


Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes , ASCO 2025, Chicago, IL : 2025


Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016) , Rapid Oral Abstract Session, ASCO 2025, Chicago, IL : 2025


Kim A. Reiss, Katherine Nathanson, Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC) , ASCO 2025, Chicago IL: 2025


Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO Treatment innovations in pancreatic cancer: putting patient priorities first , ASCO Educational Book: 2025


Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R.Pohman, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Sonawane, Sabrina Ceeraz DeLong, Melissa Christiano, Ramona F. Swaby, Sascha Abramson, Ken Locke, Debora Barton, Eugene Kennedy, Saar I. Gill, Daniel Cushing, Michael Klichinsky, Thomas Condamine, Yara Abdou Chimeric antigen receptor macrophage therapy for HER2-overexpressing advanced solid tumors: A phase 1, first-in-human clinical trial , Nature Medicine: 2025


Alison M. Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque, Eileen M. O’Reilly, Sai-Hong Ignatius Ou, Jordi Rodon Ahnert, Sun Young Rha, Kazumi Nishino, Michaël Duruisseaux, Joon Oh Park, Cindy Neuzillet, Stephen V. Liu, Benjamin A. Weinberg, James M. Cleary, Emiliano Calvo, Kumiko Umemoto, Misako Nagasaka, Christoph Springfeld, Tanios Bekaii-Saab, Grainne M. O’Kane, Frans Opdam, Kim A. Reiss, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Shola Adeyemi, Lokesh Jain, Shekeab Jauhari, Alexander Drilon Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer , NEJM: 2025


Efrat Dotan, Paul J. Catalano, Leon Lenchik, Robert Boutin, Xin Yao, James Ohr, Kian-Huat Lim, George A. Fisher Jr., Namrata Vijayvergia, Sreenivasa R. Chandana, Aparna Kalyan, Richard F. Dunne, David B. Zhen, Daneng Li, Kim A. Reiss, Melissa A. Simon, Jordan Berlin, Lynne I. Wagner, Peter J. O'Dwyer Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer , ASCO GI, San Francisco, CA: 2025


Vincent Chung, Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, Davendra Sohal, Kim Anna Reiss, Nina Niu Sanford, Carmen Allegra, Sarah Colby, Eileen M. O'Reilly, E. Gabriela Chiorean, Philip Agop Philip Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752 , ASCO GI, San Francisco, CA: 2025


Emmanuel S. Antonarakis, Katherine L. Nathanson, Kim A. Reiss, Colin C. Pritchard, Jacob E. Berchuck, Kimberly Johnson, Derek W. Brown, Hanna Tukachinsky CH mutations in 16,812 advanced cancer patients: Overestimation of CH-derived BRCA1/2 variants detected on liquid biopsy (Letter) , Clinical Cancer Research: 2025